Related Experiment Video
Updated: Feb 25, 2026
09:21
Optimized Management of Endovascular Treatment for Acute Ischemic Stroke
Published on: January 18, 2018
12.7K
Optimization of Antiplatelet Therapy in STEMI.
Abhishek Sinha1, Kush Agrawal2, Rahul Sakhuja3
1Cardiovascular Consultants Medical Group, Encino, CA, USA.
Current Treatment Options in Cardiovascular Medicine
|August 5, 2017
Summary
Newer P2Y12 inhibitors offer improved outcomes for ST elevation myocardial infarction (STEMI) patients compared to older therapies. These potent agents reduce ischemic events without significantly increasing bleeding risk, optimizing STEMI management.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Dual antiplatelet therapy (DAPT) with aspirin and clopidogrel was the standard for ST elevation myocardial infarction (STEMI).
- Advances in antiplatelet agents have introduced more potent P2Y12 inhibitors.
Purpose of the Study:
- To review the role of newer P2Y12 inhibitors in STEMI management.
- To compare the efficacy and safety of newer agents versus clopidogrel.
Main Methods:
- Review of current literature on P2Y12 inhibitors in STEMI.
- Comparative analysis of clinical trial data for prasugrel and ticagrelor versus clopidogrel.
Main Results:
- Newer P2Y12 inhibitors (prasugrel, ticagrelor) demonstrate superior reduction in ischemic endpoints compared to clopidogrel.
- These agents do not show a proportional increase in bleeding risk.
Conclusions:
- Optimizing STEMI therapy involves understanding the nuances of newer P2Y12 inhibitors.
- Combining potent agents with strategies like radial access may enhance efficacy and safety in STEMI patients.
Related Concept Videos
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
1.4K
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.4K
01:28Acute Coronary Syndrome IV: Interprofessional Care
332
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
332
01:27Peripheral Artery Disease III: Interprofessional Care
404
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
404
01:27Coronary Artery Disease V: Interprofessional Care
325
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
325
01:26Angina IV: Management
347
IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
347
01:26Atherosclerosis III: Management
482
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
482